Trending:
News
-
16 August 2018
Janssen and ViiV report positive results for two drug regimen for HIV-1
Johnson & Johnson subsidiary Janseen Pharmaceuticals and ViiV Healthcare have reported positive topline results from their phase III trial of an investigational long-acting injectable two drug regimen for the treatment...
-
16 August 2018
RXi and Karolinska Institutet target solid tumour therapy
US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with Karolinska Institutet in Stockholm, Sweden to improve immuno-oncology treatments for solid tumours.
-
16 August 2018
US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment
The US Food & Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) by Motif Bio for iclaprim, which is a targeted, Gram-positive investigational antibiotic, indicated...
-
16 August 2018
NIH-funded study reverses congenital blindness in mice
A new study funded by the National Institutes of Health (NIH) National Eye Institute (NEI) has successfully reversed congenital blindness by changing the supportive Müller glia cells in the retina...
-
15 August 2018
NICE does not recommend NHS use of Biogen’s nusinersen for SMA
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Biogen’s Spinraza (nusinersen) for routine use by the National Health Service (NHS) to treat spinal muscular atrophy...
-
15 August 2018
Study shows remifentanil better at relieving pain in labour than current standard care
An alternative opioid pain relief drug, remifentanil, can better relieve pain and reduces the need for an epidural for pregnant women during labour than the current standard of care in...
-
15 August 2018
Mustang Bio licenses gene therapy for bubble boy disease
US-based biopharmaceutical firm Mustang Bio has entered an exclusive worldwide licence agreement with St. Jude Children’s Research Hospital for a new gene therapy to treat X-linked severe combined immunodeficiency (X-SCID...
-
15 August 2018
Shire submits NDA in Japan for Intuniv to treat ADHD
Irish biotechnology company Shire, through its partner Shionogi, has filed a new drug application (NDA) in Japan seeking approval to manufacture and market its Intuniv medicine for the treatment of...
-
14 August 2018
PhRMA survey shows US biopharma exceeded R&D spending record in 2017
Spending by members of the Pharmaceutical Research and Manufacturers of America (PhRMA) on research and development (R&D) set a new record by totalling $71.4bn in 2017, according to the 2018...
-
14 August 2018
FDA approves first direct-to-consumer contraceptive app Natural Cycles
The US Food and Drug Administration (FDA) has approved Sweden-based Natural Cycles, making it the first direct-to-consumer smartphone app used for digital contraception to be marketed in the country.
